Your fact-checks will appear here
Viral vector vaccine for prevention of COVID-19
In 2020 several COVID‑19 vaccine candidates completed large phase‑3 (or phase‑2/3 seamless) trials and reported high efficacy against symptomatic disease: Pfizer–BioNTech’s BNT162b2 reported about 95%...
Animal biodistribution studies of mRNA‑LNP and adenoviral COVID‑19 vaccine platforms show different patterns: preclinical data and regulatory summaries indicate mRNA‑LNP signal concentrates at the int...
Independent researchers and public-health advocates have repeatedly flagged that raw, participant‑level datasets from several high‑profile COVID‑19 vaccine trials have not been made publicly available...
Clinical studies and case series report transient blood-test abnormalities after COVID-19 vaccination, most commonly thrombocytopenia/ITP, transient neutropenia and short-lived changes in coagulation ...
Available studies show myocarditis after mRNA COVID-19 vaccines is rare but concentrated in adolescent and young adult males (excess risk up to ~20 per 100,000 doses in some groups), venous thromboemb...
Surveillance and large cohort studies linked rare clotting with thrombocytopenia (VITT/CVST and other unusual thromboses) primarily to adenovirus‑vector vaccines (e.g., ChAdOx1) and linked myocarditis...